Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Jing PanYue TanGuoling WangBiping DengZhuojun LingWeiliang SongSamuel SeeryYanlei ZhangShuixiu PengJinlong XuJiajia DuanZelin WangXinjian YuQinlong ZhengXiuwen XuYing YuanFangrong YanZhenglong TianKaiting TangJiecheng ZhangAlex H ChangXiaoming FengPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Among 20 patients with r/r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile. A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659).
Keyphrases
- acute lymphoblastic leukemia
- study protocol
- phase iii
- clinical trial
- induced apoptosis
- phase ii
- nk cells
- open label
- randomized controlled trial
- cell cycle arrest
- rheumatoid arthritis
- systemic lupus erythematosus
- allogeneic hematopoietic stem cell transplantation
- signaling pathway
- disease activity
- cell proliferation
- cross sectional